These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
298 related articles for article (PubMed ID: 24982101)
1. Subcutaneous treprostinil for pulmonary hypertension in chronic lung disease of infancy. Ferdman DJ; Rosenzweig EB; Zuckerman WA; Krishnan U Pediatrics; 2014 Jul; 134(1):e274-8. PubMed ID: 24982101 [TBL] [Abstract][Full Text] [Related]
2. Addition of inhaled treprostinil to oral therapy for pulmonary arterial hypertension: a randomized controlled clinical trial. McLaughlin VV; Benza RL; Rubin LJ; Channick RN; Voswinckel R; Tapson VF; Robbins IM; Olschewski H; Rubenfire M; Seeger W J Am Coll Cardiol; 2010 May; 55(18):1915-22. PubMed ID: 20430262 [TBL] [Abstract][Full Text] [Related]
3. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series. Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480 [TBL] [Abstract][Full Text] [Related]
4. Bloodstream infections among patients treated with intravenous epoprostenol or intravenous treprostinil for pulmonary arterial hypertension--seven sites, United States, 2003-2006. Centers for Disease Control and Prevention (CDC) MMWR Morb Mortal Wkly Rep; 2007 Mar; 56(8):170-2. PubMed ID: 17332729 [TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of transition from subcutaneous treprostinil to oral sildenafil in patients with pulmonary arterial hypertension. Keogh AM; Jabbour A; Weintraub R; Brown K; Hayward CS; Macdonald PS J Heart Lung Transplant; 2007 Nov; 26(11):1079-83. PubMed ID: 18022071 [TBL] [Abstract][Full Text] [Related]
6. Safety and efficacy of transition from systemic prostanoids to inhaled treprostinil in pulmonary arterial hypertension. de Jesus Perez VA; Rosenzweig E; Rubin LJ; Poch D; Bajwa A; Park M; Jain M; Bourge RC; Kudelko K; Spiekerkoetter E; Liu J; Hsi A; Zamanian RT Am J Cardiol; 2012 Nov; 110(10):1546-50. PubMed ID: 22853986 [TBL] [Abstract][Full Text] [Related]
7. Treprostinil for the treatment of pulmonary arterial hypertension. Torres F; Rubin LJ Expert Rev Cardiovasc Ther; 2013 Jan; 11(1):13-25. PubMed ID: 23259441 [TBL] [Abstract][Full Text] [Related]
8. The potential for inhaled treprostinil in the treatment of pulmonary arterial hypertension. Gessler T; Seeger W; Schmehl T Ther Adv Respir Dis; 2011 Jun; 5(3):195-206. PubMed ID: 21300738 [TBL] [Abstract][Full Text] [Related]
9. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Simonneau G; Barst RJ; Galie N; Naeije R; Rich S; Bourge RC; Keogh A; Oudiz R; Frost A; Blackburn SD; Crow JW; Rubin LJ; Am J Respir Crit Care Med; 2002 Mar; 165(6):800-4. PubMed ID: 11897647 [TBL] [Abstract][Full Text] [Related]
10. Safety and efficacy of inhaled treprostinil as add-on therapy to bosentan in pulmonary arterial hypertension. Channick RN; Olschewski H; Seeger W; Staub T; Voswinckel R; Rubin LJ J Am Coll Cardiol; 2006 Oct; 48(7):1433-7. PubMed ID: 17010807 [TBL] [Abstract][Full Text] [Related]
11. The role of treprostinil in the management of pulmonary hypertension. Skoro-Sajer N; Lang I Am J Cardiovasc Drugs; 2008; 8(4):213-7. PubMed ID: 18690755 [TBL] [Abstract][Full Text] [Related]
13. Initial experience using continuous intravenous treprostinil to manage pulmonary arterial hypertension in patients with end-stage liver disease. Sakai T; Planinsic RM; Mathier MA; de Vera ME; Venkataramanan R Transpl Int; 2009 May; 22(5):554-61. PubMed ID: 19175541 [TBL] [Abstract][Full Text] [Related]
14. Safety, efficacy and Management of subcutaneous treprostinil infusions in the treatment of severe pediatric pulmonary hypertension. Levy M; Del Cerro MJ; Nadaud S; Vadlamudi K; Colgazier E; Fineman J; Bonnet D; Adatia I Int J Cardiol; 2018 Aug; 264():153-157. PubMed ID: 29650343 [TBL] [Abstract][Full Text] [Related]
15. Transitioning from i.v. epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension. Vachiéry JL; Hill N; Zwicke D; Barst R; Blackburn S; Naeije R Chest; 2002 May; 121(5):1561-5. PubMed ID: 12006444 [TBL] [Abstract][Full Text] [Related]